## IDXX: IDEXX Laboratories, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 1.1% below STRENGTH zone (4.0-10.0%); PEG 4.00 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($673.59)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 4
- **Sentiment:** Bullish (Bullish: 3, Bearish: 0)

**1. What to Expect From IDEXX Laboratoriesâ€™ Next Quarterly Earnings Report?**
- Source: inkl | 20260105T160819 | Bullish | Relevance: 100%
- IDEXX Laboratories (IDXX) is a multinational healthcare company specializing in diagnostics for animal care and water quality. Analysts anticipate the company will report a profit of $2.93 per share for fiscal Q4 2025, an 11.8% increase year-over-year. The company has consistently exceeded Wall Street's earnings estimates in the past four quarters, and its stock has significantly outperformed the S&P 500 and Health Care Select Sector SPDR Fund over the past year.

**2. IDEXX Laboratories, Inc. $IDXX Shares Acquired by Allspring Global Investments Holdings LLC**
- Source: MarketBeat | 20260104T085304 | Bullish | Relevance: 100%
- Allspring Global Investments Holdings LLC significantly increased its stake in IDEXX Laboratories, Inc. by 1,165.7% in Q3, now owning 46,489 shares valued at $28.83 million. This comes as insider Nimrata Hunt sold a substantial portion of her shares. Analysts have raised price targets for IDEXX, which maintains a "Moderate Buy" consensus rating after beating quarterly earnings and revenue expectations.

**3. IDEXX Laboratories: How a Quiet Diagnostics Giant Is Rewriting the Future of Animal Health**
- Source: AD HOC NEWS | 20260104T060839 | Bullish | Relevance: 100%
- IDEXX Laboratories has transformed veterinary diagnostics into a high-margin, high-tech platform business by integrating in-clinic analyzers, reference lab services, software, and AI tools. This ecosystem approach provides a unified workflow for veterinary practices and addresses the rising demand for sophisticated animal healthcare amidst workforce shortages. The company's unique selling proposition lies in its data and AI capabilities, workflow integration, and recurring revenue model, contributing to its strong market valuation and competitive edge against rivals like Zoetis and Antech Diagnostics.

**4. Here's Why You Should Retain Masimo Stock in Your Portfolio Now**
- Source: Finviz | 20260105T125100 | Neutral | Relevance: 59%
- Masimo Corporation is expected to see continued growth due to strong demand for its innovative technology and ongoing R&D efforts, reinforced by a solid third-quarter 2025 performance and product portfolio. Despite concerns about overreliance on its SET unit and reimbursement challenges, the company has consistently surpassed earnings estimates. Strategic partnerships and advancements in intelligent monitoring and wearables are key drivers for future growth.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-09 | Barclays | $850 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-09 | Barclays | init | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 3 ($2.08M) |
| Sells | 0 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 44.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 5 |

**Top Holders:**
- Vanguard Group Inc: 12.5% (+0.9%)
- Blackrock Inc.: 10.3% (-2.0%)
- State Street Corpora: 4.4% (-1.0%)
- Fundsmith LLP: 3.3% (-1.1%)
- Geode Capital Manage: 3.1% (+1.4%)

### Key Risks

1. Valuation stretched: PEG 4.0x requires aggressive growth execution.
2. Market regime shift could impact high-beta names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Momentum building: MRS_20 improving +3.9% over 5 days suggests accumulation.

### Fundamentals

PEG ratio 4.00 signals overvaluation risk, limited margin of safety. Forward P/E 49.0x stretched relative to 12% growth. Quality metrics strong (ROE 65%, ROA 24%, margin 25%). Insider buying signal ($2.1M), management confidence. Institutional flow bullish (5 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $56.5B |
| Beta | 1.67 |
| 52W Range | $356.14 - $769.98 |
| Short Interest | 3.4% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 4.00 |
| Forward P/E | 49.0 |
| Current P/E | 54.8 |
| YoY Growth | 11.7% |
| EPS Direction | STABLE |

### Technicals

MRS_20 strengthening from -2.9% to 1.1% (+3.9% in 5 days), confirming momentum buildup. Below STRENGTH zone by 2.9pp (needs >4.0% for momentum thesis). MRS_5 at 2.6% confirms short-term momentum alignment. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram bearish (-0.77), momentum weakening. RSI neutral at 56. OFD pattern: +FTN (Rally).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 1.09% (CS: 50) | Neutral |
| RSI_14 | 55.7 | Neutral |
| MACD Histogram | -0.77 | Bearish |
| vs SMA20 | 1.019x | Above |
| vs SMA50 | 1.013x | Above |
| vs SMA200 | 1.207x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $706.83
- **Stop Loss:** $673.59 (4.7% risk)
- **Target:** $740.07 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 39
- **Position Value:** $27,566.37
- **Portfolio %:** 27.57%
- **Risk Dollars:** $1,320.00
- **Risk Per Trade:** 1.32%
- **Modifiers:** L1 110% | L2 120% | Combined 1.32x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | RISK_ON (MEDIUM) | 1.10x |
| L2 Sector | TREND (Zone A) | 1.20x |

*RISK_ON regime with strong participation and low volatility. VIX at 14.75 (6th percentile) with breadth at 63.5% signals healthy risk appetite. Fed dovish expectations and AI/semiconductor momentum are primary drivers, though elevated put/call ratio suggests smart money hedging. Focus on quality growth with awareness of potential complacency.*

### Earnings

**Next:** 2026-02-03 (Est: $2.93)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $3.14 | $3.40 | +8.3% |
| 2025Q2 | $3.30 | $3.63 | +10.0% |
| 2025Q1 | $2.85 | $2.96 | +3.9% |
| 2024Q4 | $2.40 | $2.62 | +9.0% |

---
*RULE-based L3 | 2026-01-07 08:25 | MRS_20*